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Problem Statement/Question: Palliative Care Team (PaCT) involvement with pediatric oncology
patients improves quality of life and increases the likelihood of receiving end-of-life care consistent
with patient and family wishes. Barriers to early integration of PaCT exist. The U.S News & World
Report benchmark is >75% of patients with refractory cancer should receive PaCT consult >30
days prior to death, with our institution reporting 62% for all children with refractory cancer in
2018.
Background/Project Intent (Aim Statement):
Background: Pediatric patients with cancer diagnoses known to have a 5-year event free survival (EFS) of <
50% and treated at Children’s Mercy Hospital, Kansas City were identified between January 1, 2017 through
December 31, 2018 . 34 patients with these diagnoses died during this timeframe, and 50% had a PaCT
consult note placed >30 days prior to death. During the same timeframe, 29 patients with these diagnoses
were newly diagnosed and 27% (n=8) had a PaCT note placed within 30 days of diagnosis.
Project Intent/Aim Statement: Our global aim was to increase PaCT involvement in children with
refractorycancer diagnoses. Our primary aim was to improve the percent of patients with a PaCT team
consult note placed > 30 days prior to death from 50% to 60% for patients with target diagnoses between
March 1, 2019 to December 31, 2019. Our secondary SMART aim was to improve the percent of patients
with a PaCT note placed within 30 days of new diagnosis from 27% to 47% during the same timeframe.

Methods (include PDSA cycles):
Our PDSA cycle ramps included a division-wide survey of oncology providers identifying barriers to
consulting PaCT and an agreed list of oncologic diseases with 5-year EFS < 50% for which consultation was
recommended at the time of diagnosis (Infant acute lymphoblastic leukemia, infant acute myeloid leukemia,
diffuse intrinsic pontine glioma, high grade glioma, atypical teratoid rhabdoid, metastatic ewing sarcoma,
metastatic osteosarcoma, high risk neuroblastoma, desmoplastic small round cell tumor, alveolar high risk
rhabdomyosarcoma). A template for documenting discussion regarding PaCT team involvement was
designed and information dissemination sessions were held (Intervention # 1). We emailed monthly
reminders about the template and criteria for when PaCT consult was recommended (Intervention #2).
Reminders were emailed to primary teams within two weeks of new diagnosis (Intervention # 3). Run and
control charts assessed the impact of iterative PDSA cycles over time.

Results:
Between March 1, 2019 to December 31, 2019, 18 patients meeting criteria died and 61 % (n=11) had PaCT
consult note placed > 30 days prior to death which was an improvement from baseline of 50%. There were
14 patients with new diagnosis meeting criteria and 71 % (n=10) had PaCT consult placed within 30 days of
diagnosis which was an improvement from a baseline of 27%. Intervention # 3 was found to be the most
beneficial.

Conclusions:
We demonstrated improvement in PaCT involvement in pediatric oncology patients with 5-year EFS < 50% both
at diagnosis and > 30 days prior to death.

